Viewing
News|Articles|November 21, 2026

Q&A: GLP-1 RAs and NAION, the case for a baseline exam

James Deom, OD, MPH, FAAO, FSLS, of Hazleton Eye Specialists, explains his baseline imaging approach, his nocturnal hypotension hypothesis and his same-day workup for patients on GLP-1 RAs who have sudden vision loss.

The FDA’s November 9 safety communication required new labeling for the entire class of GLP-1 receptor agonists (GLP-1 RAs), citing a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION). The European Medicines Agency’s 2025 conclusion applied only to semaglutide, so eye care providers now face a broader counseling question as patients, prescribers, and pharmacists bring their concerns to the exam chair.

Related to this article